Page last updated: 2024-11-08

zm 241385

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ZM 241385: a high affinity radioligand selective for the A2a adenosine receptor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID176407
CHEMBL ID113142
CHEBI ID92361
SCHEMBL ID194966
MeSH IDM0255708

Synonyms (64)

Synonym
4-(2-(7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-ylamino)ethyl)phenol
HMS3267A14
BRD-K19605405-001-01-9
gtpl405
PDSP2_001185
phenol, 4-(2-((7-amino-2-(2-furanyl)(1,2,4)triazolo(1,5-a)(1,3,5)triazin-5-yl)amino)ethyl)-
4-(2-(7-amino-2-(2-furyl)(1,2,4)triazolo(2,3-a)(1,3,5)triazin-5-ylamino)ethyl)phenol
tocris-1036
NCGC00024955-01
bdbm21190
chembl113142 ,
zm 241385
4-(2-{[5-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]amino}ethyl)phenol
zm241385
NCGC00024955-02
PDSP1_001201
4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol
3EML
DB08770
L000636
4-[2-[[7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenol
zm-241,385
zm-241385
A3000
unii-5nic36bo71
5nic36bo71 ,
139180-30-6
BCPP000003
S8105
SCHEMBL194966
3PWH
7-amino-2-(2-furyl)-5-[2-(4-hydroxyphenyl)ethyl]amino[1,2,4]-triazolo[1,5-a][1,3,5]triazine
7-amino-2-(2-furyl)-5-[2-(4-hydroxyphenyl)ethyl]amino-[1,2,4]-triazolo[1,5-a][1,3,5]triazine
PWTBZOIUWZOPFT-UHFFFAOYSA-N ,
c16h15n7o2
4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol
4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)ethyl)phenol
AC-32730
AKOS024456344
DTXSID80160954
4-[2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl]phenol
HY-19532
CS-5528
EX-A944
SR-01000597469-1
sr-01000597469
CHEBI:92361
zm 241385, >=98% (hplc)
J-007249
mfcd00908394
4-(2-(7-amino-2-(furan-2-yl)-(1,2,4)triazolo(1,5-a)(1,3,5)triazin-5-ylamino)ethyl)phenol
4-(2-[7-amino-2-(2-furyl)[1,2,4]tri azolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol
HB2096
FT-0700185
HMS3676A19
BS-15358
BCP27721
HMS3412A19
Q8063128
phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-
HMS3886P04
AMY31050
HMS3742O05
CCG-267879

Research Excerpts

Treatment

ExcerptReferenceRelevance
"ZM 241385-treatment produced a statistically significant rightward displacement of CGS-21680, NECA, and CAD concentration-response curves compared with the respective controls (P < 0.05)."( Modulation of A2A adenosine receptors and associated Galphas proteins by ZM 241385 treatment of porcine coronary artery.
Mustafa, JS; Rekik, M, 2003
)
1.27

Bioavailability

ExcerptReferenceRelevance
" Many compounds within this piperazine series of [1,2,4]triazolo[1,5-a]triazine have now been shown to have good oral bioavailability in the rat, with some as high as 89% (compound 35)."( Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Chen, L; Engber, T; Grant, D; Hetu, G; Huang, C; Jin, X; Kumaravel, G; Peng, B; Petter, RC; Phadke, D; Reilly, J; Smits, G; Tam, S; Vu, CB; Zhang, J, 2004
)
0.32
" We hypothesized that the inhibition of cholinesterase activity might increase acetylcholine bioavailability and consequently cholinoceptor activation, leading to concomitant adenosine release from nerve endings and skeletal muscle fibers."( Paradoxical neostigmine-induced TOFfade: on the role of presynaptic cholinergic and adenosine receptors.
Alves-Do-Prado, W; Ambiel, CR; Antônio, MB; Correia-de-Sá, P; de Paula Ramos, E, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
"0 mg/ml) resulted in tolerance to the motor effects of an acute administration of caffeine, lack of tolerance to amphetamine, apparent tolerance to MSX-3 (shift to the left of its 'bell-shaped' dose-response curve), and true cross-tolerance to CPT."( Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration.
Antoniou, K; Ferré, S; Fuxe, K; Goldberg, SR; Justinova, Z; Karcz-Kubicha, M; Müller, CE; Pezzola, A; Popoli, P; Quarta, D; Reggio, R; Solinas, M; Terasmaa, A, 2003
)
0.32
"8% at a dosage of 5 micromol/L caffeine."( The effect of caffeine on peripheral vascular resistance in isolated perfused guinea pig hind limbs.
Brodmann, M; Lischnig, U; Lueger, A; Pilger, E; Stark, G, 2003
)
0.32
"11 for mutant F84L to 999 for two highly constitutively active mutants yielded simulated dose-response curves that mimicked the experimental curves."( ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor.
Beukers, MW; Blad, CC; Brouwer, J; den Dulk, H; Ijzerman, AP; Li, Q; Ye, K, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diamino-1,3,5-triazineAny member of the class of 1,3,5-triazines that consists of a 1,3,5-triazine skeleton substituted by two amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Purinergic signaling053

Protein Targets (46)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID886
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency17.90230.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency2.23870.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency1.33710.531815.435837.6858AID504845
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency10.00000.00207.533739.8107AID891
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
survival motor neuron protein isoform dHomo sapiens (human)Potency10.00000.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)Ki1.59800.00000.930610.0000AID1138025; AID1289971; AID1338759; AID1360946; AID1482178; AID1616541; AID1658920; AID1744269; AID1822221; AID763040; AID763041
Adenosine receptor A3Rattus norvegicus (Norway rat)IC50 (µMol)0.09490.00070.03740.0957AID1375318
Adenosine receptor A2aHomo sapiens (human)IC50 (µMol)0.02160.00071.559410.0000AID1189843; AID1338763; AID1338765; AID1360948; AID1360949; AID1402801; AID1871333; AID1874252; AID747270
Adenosine receptor A2aHomo sapiens (human)Ki30,963.50330.00001.06099.7920AID1138023; AID1280101; AID1289967; AID1338757; AID1338758; AID1360945; AID1402799; AID1402800; AID1454466; AID1482176; AID1616534; AID1618060; AID1618063; AID1626355; AID1658916; AID1696175; AID1744262; AID1810053; AID1822217; AID1854970; AID1871328; AID1874230; AID254299; AID254542; AID34235; AID365580; AID396976; AID438292; AID607198; AID747271; AID763042; AID763043
Adenosine receptor A2bHomo sapiens (human)IC50 (µMol)0.06460.00050.30231.5000AID1338760; AID1360947; AID1375318
Adenosine receptor A2bHomo sapiens (human)Ki0.05110.00021.635210.0000AID1138021; AID1272125; AID1289969; AID1482177; AID1616539; AID1658918; AID1696176; AID1744267; AID1822219; AID238419; AID438294; AID462599
Adenosine receptor A1Homo sapiens (human)Ki16,022.90530.00020.931610.0000AID1138024; AID1289965; AID1338756; AID1360944; AID1482175; AID1616537; AID1618058; AID1618062; AID1658914; AID1664166; AID1696177; AID1744264; AID1822209; AID254536; AID30443; AID396975; AID438289; AID747272
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.10730.00021.494010.0000AID1525837; AID1664167; AID239096; AID239189; AID33931
Delta-type opioid receptorMus musculus (house mouse)Ki0.00080.00000.53939.4000AID365580
Hexokinase-4Homo sapiens (human)Ki0.04200.04200.04200.0420AID438294
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.00080.00000.27869.0000AID365580
Histone deacetylase 1Homo sapiens (human)IC50 (µMol)10.00000.00010.55439.9000AID1810051
Histone deacetylase 6Homo sapiens (human)IC50 (µMol)1.00000.00000.53769.9000AID1810052
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Human Adenosine A2A receptor/T4 lysozyme chimeraHomo sapiens (human)Kd0.00180.00180.00180.0018AID977611
Chain A, Adenosine receptor A2aHomo sapiens (human)Kd0.00190.00190.00190.0019AID977611
Chain A, Adenosine receptor A2aHomo sapiens (human)Kd0.00190.00190.00190.0019AID977611
D(2) dopamine receptorHomo sapiens (human)EC50 (µMol)100.00000.00000.18743.9000AID1189844
Adenosine receptor A2aHomo sapiens (human)Kd0.00140.00020.47319.6000AID1342781; AID1342783; AID1342793; AID1342797; AID1342798; AID1342816; AID1342817; AID1342818; AID1342819; AID1342820; AID1342821; AID1798052; AID1798054; AID1874229; AID607198
Adenosine receptor A1Homo sapiens (human)Kd0.06150.00020.46215.9000AID1342822; AID1798052; AID1798054
Adenosine receptor A2aRattus norvegicus (Norway rat)Kd0.00030.00020.04910.3802AID1798054
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)INH2.04002.04002.04002.0400AID636678
Adenosine receptor A2aHomo sapiens (human)K0.00230.00100.00170.0023AID1871401
Adenosine receptor A2bHomo sapiens (human)Activity0.02800.02800.02800.0280AID1181339
Adenosine receptor A2bHomo sapiens (human)INH0.02800.02800.02800.0280AID636676
Adenosine receptor A2aRattus norvegicus (Norway rat)INH0.00030.00030.00030.0003AID636679
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (299)

Processvia Protein(s)Taxonomy
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
glucose catabolic processHexokinase-4Homo sapiens (human)
regulation of glycolytic processHexokinase-4Homo sapiens (human)
NADP metabolic processHexokinase-4Homo sapiens (human)
response to glucoseHexokinase-4Homo sapiens (human)
positive regulation of insulin secretionHexokinase-4Homo sapiens (human)
cellular response to insulin stimulusHexokinase-4Homo sapiens (human)
glucose homeostasisHexokinase-4Homo sapiens (human)
regulation of potassium ion transportHexokinase-4Homo sapiens (human)
cellular response to leptin stimulusHexokinase-4Homo sapiens (human)
negative regulation of gluconeogenesisHexokinase-4Homo sapiens (human)
positive regulation of glycogen biosynthetic processHexokinase-4Homo sapiens (human)
regulation of insulin secretionHexokinase-4Homo sapiens (human)
glucose 6-phosphate metabolic processHexokinase-4Homo sapiens (human)
canonical glycolysisHexokinase-4Homo sapiens (human)
calcium ion importHexokinase-4Homo sapiens (human)
glucose metabolic processHexokinase-4Homo sapiens (human)
intracellular glucose homeostasisHexokinase-4Homo sapiens (human)
glycolytic processHexokinase-4Homo sapiens (human)
carbohydrate phosphorylationHexokinase-4Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
chromatin organizationHistone deacetylase 1Homo sapiens (human)
chromatin remodelingHistone deacetylase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone deacetylase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
protein deacetylationHistone deacetylase 1Homo sapiens (human)
endoderm developmentHistone deacetylase 1Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 1Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
hippocampus developmentHistone deacetylase 1Homo sapiens (human)
neuron differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHistone deacetylase 1Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 1Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 1Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionHistone deacetylase 1Homo sapiens (human)
negative regulation by host of viral transcriptionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationHistone deacetylase 1Homo sapiens (human)
oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
hair follicle placode formationHistone deacetylase 1Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 1Homo sapiens (human)
fungiform papilla formationHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayHistone deacetylase 1Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayHistone deacetylase 1Homo sapiens (human)
heterochromatin formationHistone deacetylase 1Homo sapiens (human)
polyamine deacetylationHistone deacetylase 6Homo sapiens (human)
spermidine deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 6Homo sapiens (human)
protein polyubiquitinationHistone deacetylase 6Homo sapiens (human)
response to amphetamineHistone deacetylase 6Homo sapiens (human)
protein deacetylationHistone deacetylase 6Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteinsHistone deacetylase 6Homo sapiens (human)
intracellular protein transportHistone deacetylase 6Homo sapiens (human)
autophagyHistone deacetylase 6Homo sapiens (human)
actin filament organizationHistone deacetylase 6Homo sapiens (human)
negative regulation of microtubule depolymerizationHistone deacetylase 6Homo sapiens (human)
regulation of autophagyHistone deacetylase 6Homo sapiens (human)
positive regulation of epithelial cell migrationHistone deacetylase 6Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic processHistone deacetylase 6Homo sapiens (human)
regulation of macroautophagyHistone deacetylase 6Homo sapiens (human)
axonal transport of mitochondrionHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone deacetylase 6Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 6Homo sapiens (human)
protein destabilizationHistone deacetylase 6Homo sapiens (human)
lysosome localizationHistone deacetylase 6Homo sapiens (human)
protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationHistone deacetylase 6Homo sapiens (human)
cellular response to heatHistone deacetylase 6Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 6Homo sapiens (human)
response to immobilization stressHistone deacetylase 6Homo sapiens (human)
cellular response to topologically incorrect proteinHistone deacetylase 6Homo sapiens (human)
erythrocyte enucleationHistone deacetylase 6Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathwayHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
regulation of fat cell differentiationHistone deacetylase 6Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 6Homo sapiens (human)
negative regulation of proteolysisHistone deacetylase 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 6Homo sapiens (human)
collateral sproutingHistone deacetylase 6Homo sapiens (human)
negative regulation of axon extension involved in axon guidanceHistone deacetylase 6Homo sapiens (human)
positive regulation of dendrite morphogenesisHistone deacetylase 6Homo sapiens (human)
negative regulation of oxidoreductase activityHistone deacetylase 6Homo sapiens (human)
response to corticosteroneHistone deacetylase 6Homo sapiens (human)
response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHistone deacetylase 6Homo sapiens (human)
cilium assemblyHistone deacetylase 6Homo sapiens (human)
regulation of microtubule-based movementHistone deacetylase 6Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone deacetylase 6Homo sapiens (human)
dendritic spine morphogenesisHistone deacetylase 6Homo sapiens (human)
cilium disassemblyHistone deacetylase 6Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarizationHistone deacetylase 6Homo sapiens (human)
regulation of establishment of protein localizationHistone deacetylase 6Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 6Homo sapiens (human)
aggresome assemblyHistone deacetylase 6Homo sapiens (human)
polyubiquitinated misfolded protein transportHistone deacetylase 6Homo sapiens (human)
response to growth factorHistone deacetylase 6Homo sapiens (human)
cellular response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
cellular response to parathyroid hormone stimulusHistone deacetylase 6Homo sapiens (human)
response to dexamethasoneHistone deacetylase 6Homo sapiens (human)
tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of cellular response to oxidative stressHistone deacetylase 6Homo sapiens (human)
negative regulation of protein acetylationHistone deacetylase 6Homo sapiens (human)
regulation of autophagy of mitochondrionHistone deacetylase 6Homo sapiens (human)
positive regulation of cholangiocyte proliferationHistone deacetylase 6Homo sapiens (human)
negative regulation of aggrephagyHistone deacetylase 6Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (60)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
glucokinase activityHexokinase-4Homo sapiens (human)
protein bindingHexokinase-4Homo sapiens (human)
ATP bindingHexokinase-4Homo sapiens (human)
glucose bindingHexokinase-4Homo sapiens (human)
glucose sensor activityHexokinase-4Homo sapiens (human)
fructokinase activityHexokinase-4Homo sapiens (human)
mannokinase activityHexokinase-4Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 1Homo sapiens (human)
p53 bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor activityHistone deacetylase 1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 1Homo sapiens (human)
protein bindingHistone deacetylase 1Homo sapiens (human)
enzyme bindingHistone deacetylase 1Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 1Homo sapiens (human)
Krueppel-associated box domain bindingHistone deacetylase 1Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 1Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
E-box bindingHistone deacetylase 1Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 1Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 1Homo sapiens (human)
acetylspermidine deacetylase activityHistone deacetylase 6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 6Homo sapiens (human)
actin bindingHistone deacetylase 6Homo sapiens (human)
histone deacetylase activityHistone deacetylase 6Homo sapiens (human)
protein bindingHistone deacetylase 6Homo sapiens (human)
beta-catenin bindingHistone deacetylase 6Homo sapiens (human)
microtubule bindingHistone deacetylase 6Homo sapiens (human)
zinc ion bindingHistone deacetylase 6Homo sapiens (human)
enzyme bindingHistone deacetylase 6Homo sapiens (human)
polyubiquitin modification-dependent protein bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin protein ligase bindingHistone deacetylase 6Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 6Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 6Homo sapiens (human)
tubulin deacetylase activityHistone deacetylase 6Homo sapiens (human)
alpha-tubulin bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin bindingHistone deacetylase 6Homo sapiens (human)
tau protein bindingHistone deacetylase 6Homo sapiens (human)
beta-tubulin bindingHistone deacetylase 6Homo sapiens (human)
misfolded protein bindingHistone deacetylase 6Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 6Homo sapiens (human)
dynein complex bindingHistone deacetylase 6Homo sapiens (human)
transcription factor bindingHistone deacetylase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (56)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
nucleoplasmHexokinase-4Homo sapiens (human)
cytosolHexokinase-4Homo sapiens (human)
mitochondrionHexokinase-4Homo sapiens (human)
cytosolHexokinase-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleoplasmHistone deacetylase 1Homo sapiens (human)
cytoplasmHistone deacetylase 1Homo sapiens (human)
cytosolHistone deacetylase 1Homo sapiens (human)
NuRD complexHistone deacetylase 1Homo sapiens (human)
neuronal cell bodyHistone deacetylase 1Homo sapiens (human)
Sin3-type complexHistone deacetylase 1Homo sapiens (human)
histone deacetylase complexHistone deacetylase 1Homo sapiens (human)
chromatinHistone deacetylase 1Homo sapiens (human)
heterochromatinHistone deacetylase 1Homo sapiens (human)
transcription repressor complexHistone deacetylase 1Homo sapiens (human)
protein-containing complexHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 6Homo sapiens (human)
nucleoplasmHistone deacetylase 6Homo sapiens (human)
cytoplasmHistone deacetylase 6Homo sapiens (human)
multivesicular bodyHistone deacetylase 6Homo sapiens (human)
centrosomeHistone deacetylase 6Homo sapiens (human)
cytosolHistone deacetylase 6Homo sapiens (human)
microtubuleHistone deacetylase 6Homo sapiens (human)
caveolaHistone deacetylase 6Homo sapiens (human)
inclusion bodyHistone deacetylase 6Homo sapiens (human)
aggresomeHistone deacetylase 6Homo sapiens (human)
axonHistone deacetylase 6Homo sapiens (human)
dendriteHistone deacetylase 6Homo sapiens (human)
cell leading edgeHistone deacetylase 6Homo sapiens (human)
ciliary basal bodyHistone deacetylase 6Homo sapiens (human)
perikaryonHistone deacetylase 6Homo sapiens (human)
perinuclear region of cytoplasmHistone deacetylase 6Homo sapiens (human)
axon cytoplasmHistone deacetylase 6Homo sapiens (human)
histone deacetylase complexHistone deacetylase 6Homo sapiens (human)
microtubule associated complexHistone deacetylase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (179)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID244783Minimum effective dose (po) for 6-hydroxydopamine rotation in male Sprague-Dawley rats2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
AID239210Inhibition of [3H]DPCPX binding to adenosine A1 receptor of rat cerebral cortex2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
AID1626363Binding affinity to human adenosine receptor A2a His264A mutant expressed in HEK293 cell membranes assessed as level of radioligand binding at 1 uM preincubated for 1 hr followed by drug washout before [3H]-ZM241385 incubation for 30 mins by scintillation2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID1189845Agonist activity at human dopamine D2L receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay relative to 100 uM quinelorane2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
AID1189847Fraction unbound in Wistar Han rat brain at 5 uM incubated for 4 hrs by dialysis and LC-MS/MS method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
AID636676Antagonist activity at human adenosine A2B receptor2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.
AID1272788Displacement of [3H]NECA from adenosine A2A receptor in Sprague-Dawley rat striatal membrane after 1 hr by scintillation counting2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Carbamate substituted 2-amino-4,6-diphenylpyrimidines as adenosine receptor antagonists.
AID1189848Blood-brain partition ratio in Wistar Han rat at 5 uM incubated for 4 hrs by dialysis and LC-MS/MS method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
AID1360944Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membranes measured after 90 mins by scintillation counting method2018European journal of medicinal chemistry, Jul-15, Volume: 155Structure-activity relationship studies and pharmacological characterization of N
AID1626361Displacement of [3H]-ZM241385 from wild type human adenosine receptor A2a expressed in HEK293 cell membranes assessed as residence time by scintillation counting2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID1696175Antagonist activity at human adenosine 2A receptor
AID1402799Antagonist activity at adenosine A2A receptor (unknown origin)2018European journal of medicinal chemistry, Jan-20, Volume: 144Antagonists of the adenosine A
AID1482177Displacement of [3H]DPCPX from human adenosine A2B receptor expressed in HEK293 cell membranes after 30 mins2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Enantiospecific Recognition at the A
AID254555Binding affinity towards human Adenosine A2b receptor expressed in HEK293 cells using 5 nM [3H]DPCPX; nt=not tested2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID34235Binding affinity against human Adenosine A2a receptor (hA2a)2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Comparison of inhibitory activity of isomeric triazolopyridine derivatives towards adenosine receptor subtypes or do similar structures reveal similar bioactivities?
AID1664167Antagonist activity at rat A2A adenosine receptor
AID1181339Binding affinity to human adenosine A2B receptor2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5-c]pyrimidines to explore the antagonist profiling on adenosine receptors: a preliminary structure-activity relationship study.
AID1664157Displacement of [3H]DPCPX from Sprague-Dawley rat whole brain membrane A1AR by scintillation counting analysis
AID1626358Displacement of [3H]-ZM241385 from human adenosine receptor A2a StaR2-bRIL mutant expressed in HEK293 cell membranes assessed as dissociation rate constant preincubated for 2 hrs followed by ZM241385 addition measured after 2 to 6 hrs by scintillation cou2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID607198Displacement of [3H]ZM241385 from stabilized human adenosine receptor A2a expressed in HEK293 cells followed by receptor capturing on Biocore chips by SPR method2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Biophysical mapping of the adenosine A2A receptor.
AID1138023Inhibition of human recombinant adenosine receptor A2a2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID30443Binding affinity against human Adenosine A1 receptor2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
Comparison of inhibitory activity of isomeric triazolopyridine derivatives towards adenosine receptor subtypes or do similar structures reveal similar bioactivities?
AID254536Binding affinity towards human Adenosine A1 receptor expressed in CHO cells using 1 nM [3H]DPCPX2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1696177Inhibition of human adenosine A1 receptor
AID763041Competitive binding affinity to human adenosine A3 receptor expressed in CHO cells after 90 mins by flow cytometric analysis in presence of MRS54492013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID1871401Binding affinity to human adenosine A2A receptor assessed as apparent first-order rate constant(kobs)2022European journal of medicinal chemistry, Jan-05, Volume: 227Adenosine receptor antagonists: Recent advances and therapeutic perspective.
AID1338769Inverse agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as inhibition of cAMP accumulation at 10 uM measured after 150 mins in presence of [3H]cAMP by scintillation counting method relative to control2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1370517Cytotoxicity against human A549 cells assessed as cell viability at 100 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID438294Antagonist activity at human adenosine A2B receptor expressed in CHO cells assessed as inhibition of NECA-stimulated [3H]cAMP production by scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
AID396976Displacement of [3H]ZM-241385 from human cloned adenosine A2A receptor expressed in HEK293 cells by scintillation counting2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis of a series of 8-(substituted-phenyl)xanthines and a study on the effects of substitution pattern of phenyl substituents on affinity for adenosine A(1) and A(2A) receptors.
AID747272Antagonist activity at human adenosine A1 receptor assessed as cAMP level by cell based assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
AID1874228Binding affinity to human wild type adenosine A2A receptor expressed in Expi293F cells assessed as affinity off-rate by surface plasmon resonance assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.
AID763043Competitive binding affinity to human adenosine A2A receptor expressed in HEK293 cells after 60 mins by fluorescence polarization assay in presence of MRS53462013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID1360950Inverse agonist activity at human adenosine A1 receptor expressed in CHO cells assessed as cAMP accumulation at 10 uM measured after 150 mins in presence of [3H]cAMP by scintillation counting method relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Structure-activity relationship studies and pharmacological characterization of N
AID1338767Inverse agonist activity at human adenosine A1 receptor expressed in CHO cells assessed as inhibition of cAMP accumulation at 10 uM measured after 150 mins in presence of [3H]cAMP by scintillation counting method relative to control2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1626357Displacement of [3H]-ZM241385 from wild type human adenosine receptor A2a expressed in HEK293 cell membranes assessed as association rate constant after 4 hrs by scintillation counting2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID1616539Displacement of [3H]DPCPX from human recombinant A2B receptor expressed in human HEK293 cell membranes incubated for 30 mins by radioligand binding competition assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Trifluorinated Pyrimidine-Based A
AID1658916Displacement [3H]ZM241385 from adenosine A2A receptor in human HeLa cell membranes incubated for 30 mins by scintillation counting method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
AID1370515Cytotoxicity against human A549 cells assessed as cell viability at 1 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID1618063Antagonist activity at A2AR (unknown origin)2020European journal of medicinal chemistry, Feb-01, Volume: 187Identification of new potent A
AID1056823Half life in mouse at 20 mg/kg, ip by HPLC analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Design and evaluation of xanthine based adenosine receptor antagonists: potential hypoxia targeted immunotherapies.
AID636687Antagonist activity at guinea pig adenosine A2B receptor2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.
AID1626355Displacement of [3H]-ZM241385 from wild type human adenosine receptor A2a expressed in HEK293 cell membranes after 240 mins by scintillation counting2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID254299Binding affinity towards adenosine A2A receptor2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.
AID1360947Inverse agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as inhibition of cAMP accumulation measured after 150 mins in presence of [3H]cAMP by scintillation counting method2018European journal of medicinal chemistry, Jul-15, Volume: 155Structure-activity relationship studies and pharmacological characterization of N
AID1248360Displacement of [3H]-NECA from Adenosine A2A receptor in Sprague-Dawley rat striatal membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID1138024Inhibition of human recombinant adenosine A1 receptor2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID1618060Displacement of [3H]ZM241385 from human A2AR expressed in CHO cells after 90 mins by radioligand binding assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Identification of new potent A
AID1338764Inverse agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as inhibition of cAMP accumulation measured after 150 mins in presence of [3H]cAMP by scintillation counting method relative to control2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1360948Inverse agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as inhibition of cAMP accumulation measured after 150 mins in presence of [3H]cAMP by scintillation counting method2018European journal of medicinal chemistry, Jul-15, Volume: 155Structure-activity relationship studies and pharmacological characterization of N
AID1360951Inverse agonist activity at human adenosine A3 receptor expressed in CHO cells assessed as cAMP accumulation at 10 uM measured after 150 mins in presence of [3H]cAMP by scintillation counting method relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Structure-activity relationship studies and pharmacological characterization of N
AID1822219Displacement of [3H]DPCPX from human A2BAR expressed in HEK293 cell membrane incubated for 30 mins by microbeta trilux scintillation counter analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A
AID438292Displacement of [125I]Z241385 from human cloned adenosine A2A receptor expressed in CHO cells after 120 mins by scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
AID1664166Antagonist activity at human A1 adenosine receptor
AID1360952Inverse agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as cAMP accumulation at 10 uM measured after 150 mins in presence of [3H]cAMP by scintillation counting method relative to control2018European journal of medicinal chemistry, Jul-15, Volume: 155Structure-activity relationship studies and pharmacological characterization of N
AID1744262Displacement of [3H]ZM2421385 from adenosine A2A receptor expressed in human HeLa cell membranes incubated for 30 mins by scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
3,4-Dihydropyrimidin-2(1
AID1402800Displacement of [3H]-ZM241385 from human adenosine A2A receptor expressed in CHO cell membranes after 1 hr by TopCount microplate scintillation counting method2018European journal of medicinal chemistry, Jan-20, Volume: 144Antagonists of the adenosine A
AID1664162Ratio of Ki for displacement of [3H]DPCPX from Sprague-Dawley rat whole brain membrane A1AR in presence of GTP to Ki for displacement of [3H]DPCPX from Sprague-Dawley rat whole brain A1AR
AID365580Binding affinity to human adenosine A2A receptor2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.
AID747270Antagonist activity at recombinant human adenosine A2A receptor expressed in CHO cells assessed as inhibition of NECA-induced cAMP production after 60 mins2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
AID607231Binding affinity at human adenosine receptor A2a N181A'5.42 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Biophysical mapping of the adenosine A2A receptor.
AID607200Binding affinity at human adenosine receptor A2a L167A'extracellular loop 2 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Biophysical mapping of the adenosine A2A receptor.
AID1744269Displacement of [3H]NECA from adenosine A3 receptor expressed in human HeLa cell membranes incubated for 180 mins by scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
3,4-Dihydropyrimidin-2(1
AID239096Inhibition of [3H]ZM-241,385 binding to rat brain adenosine A2a receptor2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
AID763040Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cells after 90 mins by gamma counting analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID1810051Inhibition of HDAC1 (unknown origin) assessed as release of 7-amino-4-methylcoumarin incubated in room temperature for 15 min measured by Spectra max microtitre plate reader
AID1696176Inhibition of human adenosine 2B receptor
AID1375318Displacement of PSB-12105 from recombinant human adenosine A2B receptor expressed in CHO cell membranes preincubated for 30 mins followed by PSB-12105 addition measured after 20 mins by flow cytometric method2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Fluorescent-Labeled Selective Adenosine A
AID1338759Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cell membranes measured after 120 mins by scintillation counting method2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1360949Antagonist activity against human adenosine A2A receptor expressed in CHO cells assessed as inhibition of CGS21680-stimulated cAMP accumulation measured after 150 mins in presence of [3H]cAMP by scintillation counting method2018European journal of medicinal chemistry, Jul-15, Volume: 155Structure-activity relationship studies and pharmacological characterization of N
AID1189843Inhibition of human adenosine A2A receptor expressed in FlpIn-CHO cells assessed as inhibition of NECA-induced cAMP accumulation incubated for 30 mins by fluorescence assay2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
AID254542Binding affinity towards human Adenosine A2a receptor expressed in HEK293 cells using 6 nM [3H]CGS-216802005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1854970Displacement of [3H]ZM241385 from human adenosine A2A receptor expressed in HEK293 cell membrane incubated for 1 hr by microplate beta scintillation counting based radioligand inhibition assay2022European journal of medicinal chemistry, Nov-05, Volume: 241High ligand efficiency quinazoline compounds as novel A
AID238419Selectivity for recombinant human adenosine A2b receptor2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
AID607203Binding affinity at human adenosine receptor A2a I66A'2.64 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Biophysical mapping of the adenosine A2A receptor.
AID607232Inverse agonist activity at human adenosine receptor A2a S277A'7.42 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A recepto2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Biophysical mapping of the adenosine A2A receptor.
AID1626360Displacement of [3H]-ZM241385 from human adenosine receptor A2a StaR2-bRIL mutant expressed in HEK293 cell membranes assessed as residence time by scintillation counting2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID1360946Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cell membranes measured after 120 mins by scintillation counting method2018European journal of medicinal chemistry, Jul-15, Volume: 155Structure-activity relationship studies and pharmacological characterization of N
AID1744267Displacement of [3H]DPCPX from human adenosine A2B receptor expressed in HEK293 cell membranes incubated for 30 mins by scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
3,4-Dihydropyrimidin-2(1
AID1338756Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membranes measured after 90 mins by scintillation counting method2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1338771Antinociceptive activity in CD-1 mouse assessed as increase in latency in response to heat stimulus measured for 15 mins by hot water tail immersion test2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1289969Displacement of [3H]DPCPX from human Adenosine A2B receptor expressed in HEK293 cells after 30 mins2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.
AID1664161Displacement of [3H]DPCPX from Sprague-Dawley rat whole brain membrane A1AR in presence of GTP by radioligand binding assay
AID607202Binding affinity at human adenosine receptor A2a receptor Y271A'7.36 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A recept2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Biophysical mapping of the adenosine A2A receptor.
AID1822217Displacement of [3H]HZ241385 from human A2AAR expressed in HeLa cell membrane incubated for 30 mins by microbeta trilux scintillation counter analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A
AID1338763Inverse agonist activity at human adenosine A2A receptor expressed in CHO cells assessed as inhibition of cAMP accumulation measured after 150 mins in presence of [3H]cAMP by scintillation counting method2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1810049Antiproliferative activity against mouse CT26 cells measured after 72 hrs by CCK8 assay
AID239213Inhibition of [3H]DPCPX binding to rat cerebral cortex adenosine A1 receptor2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
AID1626354Displacement of [3H]-ZM241385 from human adenosine receptor A2a StaR2-bRIL mutant expressed in HEK293 cell membranes after 240 mins by scintillation counting2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID1189844Agonist activity at human dopamine D2L receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
AID636679Antagonist activity at rat adenosine A2A receptor2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.
AID1626364Binding affinity to human adenosine receptor A2a Glu169Q mutant expressed in HEK293 cell membranes assessed as level of radioligand binding at 1 uM preincubated for 1 hr followed by drug washout before [3H]-ZM241385 incubation for 30 mins by scintillation2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID1664163Selectivity index, ratio of Ki for Sprague-Dawley rat striatal membrane A2 adenosine receptor to Ki for Sprague-Dawley rat whole brain A1 adenosine receptor
AID1664159Displacement of [3H]NECA from Sprague-Dawley rat striatal membrane A2A adenosine receptor by scintillation counting analysis
AID1810052Inhibition of HDAC6 (unknown origin) assessed as release of 7-amino-4-methylcoumarin incubated in room temperature for 15 min measured by Spectra max microtitre plate reader
AID1616541Displacement of [3H]NECA from human A3 receptor expressed in human HeLa cell membranes incubated for 180 mins by radioligand binding competition assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Trifluorinated Pyrimidine-Based A
AID1338770Analgesic activity in CD-1 mouse assessed as reduction in acetic acid-induced abdominal constrictions preincubated for 15 mins followed by acetic acid challenge measured for 30 mins by writhing test2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1482178Displacement of [3H]NECA from human adenosine A3 receptor expressed in human Hela cell membranes after 180 mins2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Enantiospecific Recognition at the A
AID1370513Antiviral activity against Zika virus infected in human A549 cells preincubated for 5 hrs followed by compound wash measured after 48 hrs by viral plague-forming assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID1370514Cytotoxicity against human A549 cells assessed as cell viability at 0.1 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID1874229Binding affinity to human wild type adenosine A2A receptor expressed in Expi293F cells assessed as dissociation constant by surface plasmon resonance assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.
AID1189846Fraction unbound in Wistar Han rat blood at 5 uM incubated for 4 hrs by dialysis and LC-MS/MS method2015Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.
AID1360945Displacement of [3H]ZM241385 from human adenosine A2A receptor expressed in CHO cell membranes measured after 60 mins by scintillation counting method2018European journal of medicinal chemistry, Jul-15, Volume: 155Structure-activity relationship studies and pharmacological characterization of N
AID1871328Antagonist activity at adenosine A2A receptor (unknown origin)2022European journal of medicinal chemistry, Jan-05, Volume: 227Adenosine receptor antagonists: Recent advances and therapeutic perspective.
AID1874227Binding affinity to human wild type adenosine A2A receptor expressed in Expi293F cells assessed as affinity on-rate by surface plasmon resonance assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.
AID1289967Displacement of [3H]ZM241385 from human Adenosine A2A receptor expressed in HeLa cells after 30 mins2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.
AID1338766Antagonist activity against human adenosine A2A receptor expressed in CHO cells assessed as inhibition of CGS21680-stimulated cAMP accumulation measured after 150 mins in presence of [3H]cAMP by scintillation counting method relative to control2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1280101Displacement of [3H]-ZM241385 from human adenosine A2A receptor by scintillation spectroscopy2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
AID1338760Inverse agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as inhibition of cAMP accumulation measured after 150 mins in presence of [3H]cAMP by scintillation counting method2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1482175Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membranes after 60 mins2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Enantiospecific Recognition at the A
AID246822Effective peroral dose in rat catalepsy study2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
AID747271Antagonist activity at human adenosine A2A receptor assessed as cAMP level by cell based assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
AID1138021Inhibition of human recombinant adenosine receptor A2b2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID1356814Reversible binding to human A2AR (1 to 316 residues) expressed in Pichia pastoris SMD1168 cell membranes assessed as radioligand binding level pre-incubated at 1.4 to 4.5 nM followed by compound wash out before [3H]ZM241385 addition (Rvb = 65 +/- 2%)2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
An Affinity-Based Probe for the Human Adenosine A
AID1289965Displacement of [3H]DPCPX from human Adenosine A1 receptor expressed in CHO cells after 60 mins2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.
AID636678Antagonist activity at rat adenosine A1 receptor2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.
AID607199Binding affinity at stabilized human adenosine receptor A2a L85A'3.33 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A recep2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Biophysical mapping of the adenosine A2A receptor.
AID1272125Displacement of [3H]ZM-241385 from human A2B receptor expressed in HEK-293 cell membranes2016European journal of medicinal chemistry, Jan-27, Volume: 1085,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors.
AID396975Displacement of [3H]DPCPX from human cloned adenosine A1 receptor expressed in CHOK1 cells by scintillation counting2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis of a series of 8-(substituted-phenyl)xanthines and a study on the effects of substitution pattern of phenyl substituents on affinity for adenosine A(1) and A(2A) receptors.
AID462599Displacement of [3H]DPCPX from human recombinant adenosine A2B receptor expressed in HEK293 cell membrane2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Synthesis of theophylline derivatives and study of their activity as antagonists at adenosine receptors.
AID1338758Displacement of [3H]-CGS21680 from human adenosine A2A receptor expressed in CHO cell membranes measured after 90 mins by scintillation counting method2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1626359Displacement of [3H]-ZM241385 from wild type human adenosine receptor A2a expressed in HEK293 cell membranes assessed as dissociation rate constant preincubated for 2 hrs followed by ZM241385 addition measured after 2 to 6 hrs by scintillation counting2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID1272793Displacement of [3H]NECA from adenosine A2A receptor in rat striatal membrane2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Carbamate substituted 2-amino-4,6-diphenylpyrimidines as adenosine receptor antagonists.
AID636680Antagonist activity at rat adenosine A3 receptor2011Journal of medicinal chemistry, Feb-10, Volume: 54, Issue:3
Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.
AID1874230Binding affinity to human wild type adenosine A2A receptor expressed in Expi293F cells assessed as inhibition constant by surface plasmon resonance assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.
AID1626356Displacement of [3H]-ZM241385 from human adenosine receptor A2a StaR2-bRIL mutant expressed in HEK293 cell membranes assessed as association rate constant after 4 hrs by scintillation counting2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID1248358Displacement of [3H]-DPCPX from Adenosine A1 receptor in Sprague-Dawley rat whole brain membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID1822221Displacement of [3H]NECA from human A3AR expressed in HeLa cell membrane incubated for 180 mins by microbeta trilux scintillation counter analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A
AID1618062Antagonist activity at A1AR (unknown origin)2020European journal of medicinal chemistry, Feb-01, Volume: 187Identification of new potent A
AID1658918Displacement [3H]DPCPX from human adenosine A2B receptor expressed in HEK293 cell membranes incubated for 60 mins by scintillation counting method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
AID1454466Displacement of MRS5346 from C-terminal 10xHis and 1D4-tagged C-terminal-truncated human A2A adenosine receptor (1 to 316 residues) expressed in Pichia pastoris expression system after 1 hr by fluorescence polarization assay2017ACS medicinal chemistry letters, Jun-08, Volume: 8, Issue:6
Photoaffinity Labeling of the Human A
AID1338757Displacement of [3H]ZM241385 from human adenosine A2A receptor expressed in CHO cell membranes measured after 60 mins by scintillation counting method2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1289971Displacement of [3H]NECA from human Adenosine A3 receptor expressed in HeLa cells after 30 mins2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.
AID1616534Displacement of [3H]ZM241385 from human recombinant A2A receptor expressed in human HeLa cell membranes incubated for 30 mins by radioligand binding competition assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Trifluorinated Pyrimidine-Based A
AID1248359Selectivity ratio of Ki for Adenosine A2A receptor in Sprague-Dawley rat striatal membranes to Ki for Adenosine A1 receptor in Sprague-Dawley rat whole brain membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID1810053Displacement of [3H]SCH58261 from adenosine A2A receptor membrane (unknown origin) measured after 60 mins by scintillation counting analysis
AID1658914Displacement [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membranes incubated for 60 mins by scintillation counting method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
AID1482176Displacement of [3H]4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol from human adenosine A2A receptor expressed in human Hela cell membranes after 30 mins2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Enantiospecific Recognition at the A
AID1871333Inverse agonist activity at human A2A receptor assessed as inhibition of cAMP accumulation2022European journal of medicinal chemistry, Jan-05, Volume: 227Adenosine receptor antagonists: Recent advances and therapeutic perspective.
AID1871335Antinociceptive activity in mouse measured by writhing test2022European journal of medicinal chemistry, Jan-05, Volume: 227Adenosine receptor antagonists: Recent advances and therapeutic perspective.
AID1338765Antagonist activity against human adenosine A2A receptor expressed in CHO cells assessed as inhibition of CGS21680-stimulated cAMP accumulation measured after 150 mins in presence of [3H]cAMP by scintillation counting method2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1744264Displacement of [3H]DPCPX from human adenosine A1 receptor expressed in CHO cell membranes incubated for 60 mins by scintillation counting method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
3,4-Dihydropyrimidin-2(1
AID239189Inhibition of [3H]ZM-241385 binding to adenosine A2a receptor of rat brain tissue2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
AID438296Antagonist activity at human cloned adenosine A3 receptor expressed in CHO cells assessed as inhibition of Cl-IB-MECA-inhibited [3H]cAMP production at 1 uM by scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
AID1822209Displacement of [3H]DPCPX from human A1AR expressed in CHO cell membrane incubated for 60 mins by microbeta trilux scintillation counter analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A
AID1658920Displacement [3H]NECA from adenosine A3 receptor in human HeLa cell membranes incubated for 180 mins by scintillation counting method2020Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A
AID1618058Displacement of [3H]DPCPX from human A1AR expressed in CHO cells incubated for 50 mins by radioligand binding assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Identification of new potent A
AID438287Inhibition of [125I]AB-MECA binding to human cloned adenosine A3 receptor expressed in CHO cells at 1 uM after 120 mins by scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
AID250010Compound was tested in mouse catalepsy study (po); inactive at 10 mg/kg2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
AID1874252Antagonist activity at human adenosine A2A receptor expressed in HEK293T cells assessed as inhibition of NECA-induced Gs short protein activation by TRUPATH assay2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.
AID1338768Inverse agonist activity at human adenosine A3 receptor expressed in CHO cells assessed as inhibition of cAMP accumulation at 10 uM measured after 150 mins in presence of [3H]cAMP by scintillation counting method relative to control2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A
AID1616537Displacement of [3H]DPCPX from human recombinant A1 receptor expressed in CHOA1 cell membranes incubated for 60 mins by radioligand binding competition assay2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Trifluorinated Pyrimidine-Based A
AID1626362Binding affinity to wild type human adenosine receptor A2a expressed in HEK293 cell membranes assessed as level of radioligand binding at 1 uM preincubated for 1 hr followed by drug washout before [3H]-ZM241385 incubation for 30 mins by scintillation coun2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.
AID1138025Inhibition of human recombinant adenosine A3 receptor2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Adenosine A2A receptor as a drug discovery target.
AID1402801Antagonist activity at human adenosine A2A receptor expressed in HEK293 cell membranes assessed as inhibition of CGS241680-induced [35S]GTPgammaS binding preincubated for 10 mins followed by CGS241680 addition by TopCount scintillation counting method2018European journal of medicinal chemistry, Jan-20, Volume: 144Antagonists of the adenosine A
AID33931Displacement [3H]-CGS-21,680 from Adenosine A2A receptor in rat striatal membrane.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.
AID438289Displacement of [125I]DPCPX from human cloned adenosine A1 receptor expressed in CHO cells after 120 mins by scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
AID1525837Displacement of [3H]NECA from rat adenosine A2A receptor expressed in CHO cell membranes by radioligand competition assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-
AID763042Displacement of [3H]CGS21680 from human adenosine A2A receptor expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Fluorescent ligands for adenosine receptors.
AID1248370Displacement of [3H]-NECA from Adenosine A2A receptor in rat striatal membranes2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.
AID1261638Displacement of [3H]NECA from adenosine A2A receptor in Sprague-Dawley rat striatal membranes after 1 hr by scintillation counting analysis2015European journal of medicinal chemistry, Nov-02, Volume: 1042-Aminopyrimidines as dual adenosine A1/A2A antagonists.
AID1810050Antiproliferative activity against mouse MC38 cells measured after 72 hrs by CCK8 assay
AID1370516Cytotoxicity against human A549 cells assessed as cell viability at 10 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID607201Binding affinity at human adenosine receptor A2a M177A'5.38 mutant expressed in HEK293 cells followed by receptor capturing on Biocore chips assessed as log difference in receptor affinity by SPR method relative to wild type stabilized A2A receptor2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Biophysical mapping of the adenosine A2A receptor.
AID255370Selective binding affinity towards human Adenosine A1 receptor expressed in CHO cells using [3H]DPCPX compared to human Adenosine A2a receptor expressed in HEK293 cells using [3H]-CGS-21,6802005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1345685Human A1 receptor (Adenosine receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 359, Issue:1
Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.
AID1345685Human A1 receptor (Adenosine receptors)2006Nature reviews. Drug discovery, Mar, Volume: 5, Issue:3
Adenosine receptors as therapeutic targets.
AID1345721Human A2B receptor (Adenosine receptors)2004Biochemical pharmacology, Jul-15, Volume: 68, Issue:2
[3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors.
AID1345721Human A2B receptor (Adenosine receptors)2000Molecular pharmacology, Dec, Volume: 58, Issue:6
Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine.
AID1345721Human A2B receptor (Adenosine receptors)2001Biochemical pharmacology, Mar-15, Volume: 61, Issue:6
[3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors.
AID1345721Human A2B receptor (Adenosine receptors)1999Molecular pharmacology, Oct, Volume: 56, Issue:4
Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells.
AID1345618Human A2A receptor (Adenosine receptors)1999Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 359, Issue:1
Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.
AID1345822Human A3 receptor (Adenosine receptors)2006Nature reviews. Drug discovery, Mar, Volume: 5, Issue:3
Adenosine receptors as therapeutic targets.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2008Science (New York, N.Y.), Nov-21, Volume: 322, Issue:5905
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.
AID1798054Receptor Binding Assay from Article 10.1021/jm701187w: \\2-Amino-N-pyrimidin-4-ylacetamides as A2A Receptor Antagonists: 2. Reduction of hERG Activity, Observed Species Selectivity, and Structure-Activity Relationships.\\2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships.
AID1798052Receptor Binding Assay from Article 10.1021/jm701185v: \\2-Amino-N-pyrimidin-4-ylacetamides as A2A Receptor Antagonists: 1. Structure-Activity Relationships and Optimization of Heterocyclic Substituents.\\2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituents.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011Structure (London, England : 1993), Sep-07, Volume: 19, Issue:9
Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (397)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's45 (11.34)18.2507
2000's207 (52.14)29.6817
2010's128 (32.24)24.3611
2020's17 (4.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.13 (24.57)
Research Supply Index6.00 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.75%)5.53%
Reviews8 (2.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other390 (97.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]